Trial Information
International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC)
Inclusion Criteria:
- In- and outpatients with diagnosis of hepatocellular carcinoma (HCC) and decision
taken by the investigator to prescribe Nexavar
Exclusion Criteria:
- Exclusion criteria must be read in conjunction with the local product information
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Efficacy: status of tumor, patients performance status
Outcome Time Frame:
At each follow-up visit, every 2-4 months
Safety Issue:
No
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
14690
NCT ID:
NCT00792350
Start Date:
April 2008
Completion Date:
December 2013
Related Keywords:
- Carcinoma, Hepatocellular
- Carcinoma, Hepatocellular
- Sorafenib
- Carcinoma
- Carcinoma, Hepatocellular